Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 17/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.54 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.54 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6626334 | 1.00 | BCHE (0.59) | BCHEKDM4EL3MBTL1PTGER4PTGER3 | |
| SCHEMBL4225323 | 0.87 | KDM4E (0.59) | BCHEKDM4EL3MBTL1PTGER4PTGER3 | |
| SCHEMBL28129636 | 0.82 | KDM4E (0.65) | BCHEKDM4EL3MBTL1PTGER4PTGER3 | |
| SCHEMBL6035893 | 0.81 | BCHE (0.68) | BCHEKDM4EL3MBTL1 | |
| SCHEMBL28129637 | 0.79 | BCHE (0.61) | BCHEKDM4EL3MBTL1 | |
| SCHEMBL3056582 | 0.79 | BCHE (0.64) | BCHEKDM4EL3MBTL1 | |
| SCHEMBL9802685 | 0.77 | BCHE (0.60) | BCHEKDM4EL3MBTL1 | |
| SCHEMBL9741673 | 0.77 | ABCB1 (0.47) | — | |
| SCHEMBL13888119 | 0.77 | BCHE (0.69) | BCHEKDM4EL3MBTL1 | |
| SCHEMBL6626649 | 0.76 | MEN1 (0.42) | KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1564818-A | Stereoselective synthesis method of 2-hydroxymethyl-chroman | WYETH CORP (US) | 2005-01-12 | — | — | CN | disclosed |
| US-6667322-B2 | Useful for treatment of diseases such as obsessive compulsive disorder, panic attacks, anxiety, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-12-23 | — | — | US | disclosed |
| US-20030100579-A1 | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole | WYETH | 2003-05-29 | — | — | US | disclosed |
| WO-2003031439-A1 | ANTIDEPRESSANT CHROMAN AND CHROMENE DERIVATIVES OF 3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE | WYETH (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100579-A1 | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole | TPH1, HTR1D, HTR1A | BCHE 3226/4885KDM4E 1571/4885L3MBTL1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.